KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) major shareholder Holdings A/S Novo sold 25,900 shares of the business’s stock in a transaction that occurred on Wednesday, September 13th. The shares were sold at an average price of $8.02, for a total value of $207,718.00. Following the completion of the transaction, the insider now directly owns 2,876,027 shares in the company, valued at approximately $23,065,736.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Holdings A/S Novo also recently made the following trade(s):

  • On Thursday, September 14th, Holdings A/S Novo sold 10,000 shares of KalVista Pharmaceuticals stock. The stock was sold at an average price of $8.05, for a total value of $80,500.00.
  • On Friday, September 15th, Holdings A/S Novo sold 176,647 shares of KalVista Pharmaceuticals stock. The stock was sold at an average price of $7.21, for a total value of $1,273,624.87.

KalVista Pharmaceuticals, Inc. (NASDAQ KALV) traded down 13.11% during trading on Friday, hitting $6.96. The stock had a trading volume of 162,624 shares. The firm’s market cap is $67.60 million. The firm’s 50 day moving average is $8.20 and its 200 day moving average is $7.83. KalVista Pharmaceuticals, Inc. has a 1-year low of $6.09 and a 1-year high of $10.65.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings results on Thursday, September 14th. The specialty pharmaceutical company reported ($0.51) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.08. KalVista Pharmaceuticals had a negative return on equity of 63.41% and a negative net margin of 5,863.31%. The business had revenue of $0.10 million for the quarter. On average, analysts anticipate that KalVista Pharmaceuticals, Inc. will post ($2.94) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “KalVista Pharmaceuticals, Inc. (KALV) Major Shareholder Holdings A/S Novo Sells 25,900 Shares” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of international copyright laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/09/15/kalvista-pharmaceuticals-inc-kalv-major-shareholder-holdings-as-novo-sells-25900-shares.html.

A number of research analysts recently weighed in on the company. BTIG Research assumed coverage on KalVista Pharmaceuticals in a report on Thursday, August 31st. They set a “buy” rating and a $18.00 price objective on the stock. ValuEngine upgraded KalVista Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, August 2nd.

An institutional investor recently bought a new position in KalVista Pharmaceuticals stock. Eventide Asset Management LLC acquired a new stake in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 98,100 shares of the specialty pharmaceutical company’s stock, valued at approximately $766,000. Eventide Asset Management LLC owned about 1.01% of KalVista Pharmaceuticals at the end of the most recent quarter. Hedge funds and other institutional investors own 75.66% of the company’s stock.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, formerly Carbylan Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME).

Receive News & Ratings for KalVista Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.